Related references
Note: Only part of the references are listed.Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center
Lukasz Kwapisz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease
Edward Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
Christine Olbjorn et al.
PEDIATRIC DRUGS (2020)
Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab
Giuseppe Biscaglia et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2019)
Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
Robert P. Hirten et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics
Eric J. Mao et al.
BMJ OPEN GASTROENTEROLOGY (2018)
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
Eddie Y. Liu et al.
CASE REPORTS IN MEDICINE (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
Elaheh Vahabnezhad et al.
INFLAMMATORY BOWEL DISEASES (2014)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD (Reprinted from Gastroenterology Clinics of North America, vol 38)
Cary G. Sauer et al.
MEDICAL CLINICS OF NORTH AMERICA (2010)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Share Paper
